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Abstract 
 
 By their nature, stem cells present a strong potential in regenerative medicine. Recent 
medical research is noticing this potential as stem cell therapies are becoming more and more 
commonplace. With new therapies being proposed and developed, questions are raised about the 
specific factors that play significant roles in affecting the biology of these cells. The research focus 
of our group is bone tissue regeneration, and we use the mouse MC 3T3-E1 preosteoblast cell line 
as a model to study changes during bone cell differentiation.  These cells are studied to establish 
molecular and cellular assays to assess bone cell proliferation, differentiation, and visualization.  
The results from these cells will then be translated to adult stem cells undergoing bone formation.  
Cell proliferation assays were validated to obtain the optimal seeding density and optimal fetal 
bovine serum contained in the medium for growth and expansion of MC 3T3-E1 cells. Optimal 
concentrations of the biological factors dexamethasone, ascorbic acid, and betaglycerophosphate 
required for efficient bone cell differentiation have also been optimized.  The differentiation 
process was evaluated microscopically and confirmed by a calcium-specific staining.  
Undifferentiated cells were used as controls.  For clinical application, we did a dose curve to assess 
the concentration of tobramycin, an antibiotic that is administered subsequent to the addition of 
stem cells to damaged joints.  Cells showed surprising tolerance to tobramycin between 0 to 360 
g/mL.  The proliferation of cells suffered significantly at doses greater than 360 g/mL. Further 
experiments are currently in progress to study and visualize MC 3T3-E1 cells. These include the 
development of a DNA plasmid to visualize bone cell differentiation consisting of a green 
fluorescent protein under the control of the osteocalcin promoter with a constitutively active m-
cherry protein. Additionally, we are studying stem cell behavior on a novel polymer-
hydroxyapatite – based biocomposite material with a long term goal of using it in bone defect 
regeneration. 
 
 
 
Introduction 
 
 The discovery of stem cells has 
opened the door to many new therapies that 
were impossible a few decades ago. In 
developing zygotes and fetuses, stem cells 
are the first cells that mature into the many 
tissues of the body. In adults, there are 
stockpiles of stem cells that serve to replenish  
 
 
These cells throughout the life of the 
organism. Stem cells are often quick to divide 
and expand, and they have the ability to 
become many different cells (multipotency). 
By utilizing this natural process of cell 
replacement, stem cell therapies produce new 
tissues for a variety of maladies [1]. Stem 
cells from a different individual can be given 
as an allograft transplant to provide some 
advantage that the patient’s own tissues do 
not afford [2]. Alternatively, a patient’s own 
stem cells (autograft) can be modified and 
replaced to produce therapeutic effects such 
as specific gene knockouts [3]. Finally, 
though not exhaustively, stem cells can be 
removed and expanded from an individual 
and then returned in a new location or in large 
number to provide a benefit to the patient [4].  
 
 Stem cells can generally be divided 
into four categories: embryonic stem cells, 
fetal stem cells, induced pluripotent stem 
cells (iPS), and somatic/adult stem cells. 
Embryonic and fetal stem cells are derived 
from developing organisms. While they 
represent many possible directions in 
medicine, these sources of stem cells carry 
the risk of hyperproliferation and cancer 
formation, and their collection in humans is 
often politicized and ethically debated. iPS 
cells are produced by treatment of lineage-
restricted cells with transcription factors that 
result in pluripotency [1]. This is another 
promising route for stem cell therapy, but 
degrees of uncertainty in the methods for iPS 
creation and iPS biology represent challenges 
to their use in humans [5]. Considering the 
issues with the above methods, adult-derived 
somatic stem cells remain the best candidate 
for most stem cell treatments. Mesenchymal 
Stem Cells (MSC) are somatic stem cells that 
have the capacity to differentiate into tissues 
of the blood, cartilage, bone, and more. They 
can be isolated from bone marrow and fat 
tissues and serve as reasonably safe, reliable 
sources of stem cells [1]. 
 
 The capability of MSCs to 
differentiate into the cells of the skeletal 
system make them ideal for use in bone tissue 
regeneration. For most bone defects, such as 
fractures, bone regenerates naturally. For 
larger defects, such as surgical removal of a 
large bone cyst, a bone graft may be needed 
to aid in healing. Historically, bone grafts 
have been taken from other parts of the body 
and shaped for the new defect. This method, 
autograft bone transplantation, has many 
drawbacks such as risk of donor and recipient 
site complications and inexact fit of the graft 
[6].  
 
 By using stem cell therapy to add 
MSCs to bone defect sites, the Dhar lab at the 
University of Tennessee, Knoxville College 
of Veterinary Medicine works to develop 
treatments that circumvent the risks 
associated with autograft bone tissue 
transplant. Further, the characteristic 
potential of stem cells makes them ideal for 
use in more novel therapies, which our lab 
endeavors to discover and expand upon. 
 
 The ultimate goal for our research is 
to develop medical procedures in humans. 
The road to human trials, however, is 
understandably long and difficult. Before this 
is a possibility, treatments must be explored 
in small and large animal models such as 
mice and goats. Our lab has shown promising 
success of several therapies in animal 
models, and we have begun to use these 
techniques on large animal veterinary 
patients [7] [8]. 
 
 MC 3T3-E1 is a cell line of mouse 
(Mus musculus) calvaria preosteoblast cells. 
Commonly used for studies concerning bone 
differentiation and development, the 
textbook Principles of Bone Biology refers to 
them as “one of the most convenient and 
physiologically relevant systems for study of 
transcriptional control in calvarial 
osteoblasts.” MC 3T3-E1 is a spontaneously-
immortalized cell line that behaves as 
immature, committed osteoblast cells. The 
cell phenotype is very stable so long as stocks 
are rigorously maintained [9].  
   
 Science uses models to reliably 
simulate a system that would be too time-
consuming, difficult, expensive, or otherwise 
inappropriate to test as a whole. Similarly, it 
would be inappropriate to test an entirely 
novel treatment method on a group of lab 
animals. Instead, treatments and new 
questions should first be explored in vitro 
with a suitable line of cells as a model. That 
starting point is the goal of this project – the 
establishment of an in vitro model for stem 
cell-mediated bone regeneration in our lab. 
Here, we use MC 3T3-E1 mouse 
preosteoblast cells towards this end. The cells 
are characterized to confirm and explore 
ideal conditions; they are studied to establish 
factors and time points in the process of 
differentiation; and they are used in ongoing 
projects to visualize them in vitro and test 
new therapeutic materials.  
  
 
 
Characterization  
 
Establishment 
 
 One million cryopreserved MC 3T3-
E1 cells were purchased from American 
Type Culture Collection (ATCC) in August 
2015. After returning the cells to liquid 
nitrogen for one month, we removed and 
quickly thawed them in a 37C water bath. 
The thawed cells were added to 10mL of 
media, placed in a 75 cubic centimeter cell 
culture flask (T75), and incubated at 37C 
with 5% CO2. We changed the cell media 
every 48 to 72 hours.  
 
Passaging 
 
Once the cells reached confluency, 
we washed the cells with Hank’s Balanced 
Salt Solution (HBSS), removed cells from the 
flask surface with with 5mL of 0.25% trypsin 
incubated at 37C for two minutes, and then 
inactivated the trypsin by adding 5mL of 
media. Next, we pipetted the resulting 10mL 
into a 50 mL conical tube and centrifuged it 
at 3000 RPM for 10 minutes. We found that 
cells have a tendency to form aggregates after 
centrifugation, especially when centrifuged 
in smaller 15 mL tubes. The supernatant was 
removed following centrifugation, the pellet 
was disturbed and suspended in 2 mL of 
media, and the suspension was chilled on ice 
for 10 minutes. If cell aggregates persisted 
after thorough mixing, they were removed by 
micropipette.  
  
Counting 
 
 We diluted cells 1:20 with trypan blue 
(20 L cell suspension in 380 L trypan blue) 
and counted by adding 10 L of the dilution 
to a hemocytometer and counted 5 of the 
1mm2 grids which held 100 nL each. We 
calculated total cells by the formula 
𝑐𝑜𝑢𝑛𝑡 ∗ 20 ∗
1
5
 ∗
1
100
∗ 106 =
𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
 
 
Growing cells 
 
 The primary media used to grow cells 
was alpha Minimum Essential Medium 
(MEM) with 10% US qualified, heat 
inactivated fetal bovine serum (FBS) and 1% 
penicillin/streptomycin antibiotic mixture 
(pen/strep; 10,000units/mL pen; 10,000 
g/mL strep). Media was stored at 4C and 
warmed before addition to cells. Cells did not 
grow well when seeded at low density (below 
5000 cells/cm2) which suggests a dependence 
on cell-cell interactions for normal 
proliferation. Healthy cells maintained a 
relatively round morphology (Figure 1.) with 
few instances of cell death. The MC 3T3-E1 
cells proved to grow very quickly. 300,000 
cells plated in a 75mm flask reach numbers 
of 2.3 million (stdev 250,000) cells after 
incubation for 5 days.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum Test 
 
We wanted to know if the type of FBS 
used has an effect on MC 3T3-E1 
proliferation. We tested three types of serum 
with MEM and pen/strep:  
 
1. US qualified, heat inactivated FBS 
2. Non US qualified, heat inactivated FBS 
3. Non US qualified, non heat inactivated FBS 
 
We found slight variation in the relative 
proliferation, but we show no evidence to 
support preferential use of US qualified, heat 
inactivated FBS (#1), the most labor-
intensive and expensive option.  
Consequently, we suggest the use of non US 
qualified, non heat inactivated FBS (#3) as it 
is the most cost effective (figure 2.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differentiation 
 
 Stem cell therapy of the skeletal 
system largely has the goal of using stem 
cells to regenerate healthy bone tissue in the 
patient. This differentiation process would 
happen naturally in the body by diffusion of 
factors that lead to differentiation into bone 
cells. To study this process and see how 
treatments affect bone differentiation, our lab 
must reliably simulate this development in 
vitro. We sought to determine a set of factors 
and a base timeline for bone formation in 
these cells.  
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Figure 1.  The cell counts from each replicate 
were divided by that replicate’s maximum count 
to show relative proliferation. Cells were 
incubated for 5 days in MEM with pen/strep and 
three different types of FBS.  1. US qualified, heat 
inactivated FBS  2. Non US qualified, heat 
inactivated FBS  3. Non US qualified, Non heat 
inactivated FBS.  
Figure 2.  Images of cells incubated with and 
without differentiation factors after staining with 
Alizarin Red. 2a. undifferentiated cells after 20 
days of incubation in regular media. 2b. cells 
after 14 days of incubation with differentiation 
factors. 2c. Cells after 20 days of incubation with 
differentiation factors. 
b.  
c.  
a.  
Growth  
 
Citing the work of Kanzaki et al., we 
found that the following concentrations of 
factors leads to ossification of MC 3T3-E1 
cells [10]: 
 
 50 g/mL ascorbic acid 
 10 mmol/L β-glycerophosphate  
 10 nmol/L dexamethasone 
 
We tested for bone differentiation by 
growing MC 3T3-E1 cells in 6-well plates at 
initial density of 20,790 cells/cm2. The 6-
well, 9.62 cm2 well plates were purchased 
from Thermofisher. Every 36 to 48 hours, 
half of the wells were fed differentiation 
media with the above concentrations of 
factors, and half were kept as controls and 
grown in normal media.  
 
Staining 
 
We fixed the cells for staining at time 
points between 7 and 24 days. For washing, 
fixing, and staining, approximately 1.5mL of 
each reagent was added by plastic pipette. We 
washed the cells twice with HBSS and then 
fixed them with 4% paraformaldehyde for 10 
minutes at room temperature. Following this, 
we washed two additional times with HBSS 
and then added Alizarin Red stain. After cells 
were stained for 30 minutes, we removed 
Alizarin Red, washed twice with HBSS, and 
allowed the stained plates to dry. As per the 
manufacturer’s directions, the Alizarin Red 
solution was prepared by adding 1.7 g of 
Alizarin Red to 100 mL of DI H2O. The pH 
was then adjusted to 4.1 to 4.3 with 
ammonium hydroxide. The final volume was 
brought to 50 mL. Alizarin Red is a calcium 
specific stain. Adding it to cells that are 
becoming bone tissue allows us to visualize 
calcium deposition and infer ossification.  
 
 
 
 
Results 
 
 After incubation in the 
aforementioned factors, we show that the MC 
3T3-E1 cells begin the process of bone 
differentiation. By the 7th day of growth in 
differentiation media, cell morphology 
noticeably changes, and the cell monolayer 
tends to develop into a swirling pattern 
compared to undifferentiated controls. Upon 
fixing and staining, we found that cells grown 
in the 6-well plates begin depositing calcium 
after approximately 14 days of incubation in 
the differentiation factors (Figure 2b.). By 
the 16th day, the amount of calcium deposits 
significantly increases. By 20 days, the 
Alizarin Red calcium staining is very heavy 
(Figure 2c.). We found that specific culture 
conditions, such as initial density or culture 
surface, had a large impact on the timeline of 
cell differentiation. For example, cells grown 
at 7,074 cells/cm2 in 60 mm, biolite 
individual tissue culture dishes purchased 
from Thermofisher took significantly longer 
to deposit calcium. (21 days compared to 14 
days). For the sake of this experiment, results 
are shown from 6-well plates. 
  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tobramycin dose curve 
 
 When surgeries are performed on 
animal models or in veterinary medicine for 
stem cell transplantation, these patients are 
often given antibiotics post operation to 
prevent infection. One of the most commonly 
used antibiotics for this end is Tobramycin, 
an aminoglycoside antibiotic. Tobramycin 
inhibits protein synthesis in gram-negative 
bacteria by irreversibly binding to the 30S 
ribosomal subunit [11]. As part of our goal to 
establish MC 3T3-E1 cells as a dependable 
model in our lab, we wanted to ensure that the 
drug to be used during subsequent in vivo 
models does not adversely affect MC3T3-E1 
proliferation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 
We seeded 96-well plates with 
2200 cells/well at a density of 6,832 
cells/cm2. We fed the cells media with 
MEM and 10% FBS, but without antibiotic 
to avoid error caused by drug interaction such 
as degradation of tobramycin by penicillin 
[12]. Recognizing the risk of growing cells 
without antibiotics, extra care was taken to 
avoid bacterial contamination. We waited 24 
hours to ensure that cells attached before 
adding TOB; at that point, cells were given 
TOB at concentrations of 0, 0.4, 5, 80, 360, 
720, and 1440 g/mL. We quantified 
proliferation by MTS assay, a colorimetric 
method where MTS tetrazolium compound is 
reduced by NAD(P)H-dependent 
dehydrogenase enzymes in metabolically-
active cells. This results in a change in 
absorbance at 490 nm corresponding to the 
Figure 3.  MTS assay results from cells grown in different concentrations of tobramycin. Tobramycin is toxic 
to cells above 360 g/mL which is well above expected in vivo level; this suggests low toxicity to MC3T3-
E1 cells. 
 
Figure 5.  MTS assay results from cells grown in different concentrations of tobramycin. Tobramycin is toxic 
to cells above 360 g/mL which is well above expected in vivo level; this suggests low toxicity to MC3T3-
E1 cells. 
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cell count [13]. We took readings in triplicate 
on days 4, 8, 14, and 28.  
Results 
 
 Cells grown between 0 and 360 
g/mL of TOB showed no diminished 
proliferation. At concentrations of 720 and 
1440 g/mL, MC3T3-E1 proliferation 
suffered significantly. Even at the highest 
tested concentrations, the cells were less 
affected by TOB at earlier time points but 
greatly affected at later points (Figure 3.). 
 
 In vivo levels of TOB would be 
unlikely to exceed 10 g/mL [14]. Even if an 
injection of TOB were given directly or near 
to the site of stem cell transplant, our data 
show that short-term exposure to TOB 
presents less toxicity compared to long-term 
exposure. These findings suggest little risk 
associated with in vivo use of TOB with 
MC3T3-E1 cells. 
 
 
 
Future directions  
 
Visualization 
 
 Working with Dr. Tom Masi at the 
University of Tennessee Medical Center, we 
are developing a DNA vector to allow 
visualization of bone cell differentiation in 
real time without fixing the cells i.e. without 
having to stop the experiment. The completed 
DNA vector will have two fluorescent 
protein genes, an m-cherry gene (Excitation 
wavelength: 587 nm, Emission: 610 nm) and 
a green fluorescent protein gene (GFP) 
(Excitation: 395 nm, Emission: 509 nm). The 
m-cherry gene will be constitutively on so 
that undifferentiated cells fluoresce red. The 
GFP gene will be under the control of the 
osteocalcin promoter. Osteocalcin is a 
protein synthesized by osteoblasts and is  
 
 
 
 
 
associated with bone mineralization [15]. 
Figure 4. Shows the DNA vector makeup. 
When the 3T3-E1 cells begin functioning as 
osteoblasts, the cell fluorescence should 
change. This will allow us to visualize the 
process of bone differentiation in living cells.  
 
 We have optimized a procedure for 
the transfection of a positive control plasmid 
with a constitutively active m-cherry gene 
(Figure 5.). We used polyethylenimine (PEI) 
as a transfection reagent. We experimented 
with different ratios of DNA to PEI (1:1, 1:2, 
1:3) and found that the 1:3 ratio provides the 
best degree of transfection. Additionally, we 
tested to see the ideal time of incubation with 
DNA and PEI (2 hours, 6 hours, 24 hours), 
and found 6 hours to be the most successful. 
To transfect cells in 24 well plates seeded at 
25,000 cells/ cm2, we changed all cell media 
to antibiotic-free. For 1:3 ratio, we added 
24uL of 1mg/mL PEI solution to 50 uL 
MEM to vial 1.  
 
 
 
 
 
Figure 4.  DNA vector makeup for 3T3-E1 bone 
differentiation visualization. As transfected cells 
differentiate, the fluorescence should change 
from red to green.  
  
 
 
 
 
 
 
 
 
 
 
 
 
In vial 2, we added 8uL of 1ug/mL DNA to 
50 uL MEM. We then combined vials 1 and 
2 and allowed them to rest at RT for 10 
minutes. 33 uL of this mixture was added to 
each well and removed after 6 hours. 
 
Biomaterial  
 
 Our lab has begun testing novel 
treatments using 3T3-E1 cells as a model. 
With the Nanotechnology Center at 
University of Arkansas at Little Rock, we are 
testing the potential use of a polymer-
hydroxyapatite biomaterial for use in stem 
cell-mediated bone regeneration. In this 
collaboration, our labs hope to develop a 
material that can be transplanted into bone 
defects along with mesenchymal stem cells. 
Ideally, the biomaterial would provide a 
slow-degrading scaffold onto which new 
bone could grow. By adding stem cells to the 
material, this process could be expedited for 
quicker and better healing.  
 
 We are assessing the cytotoxicity of 
the material, and we are determining the ideal 
ratios of polymer and hydroxyapatite for 
ideal cell infiltration (Figure 6.). 
 
 
 
 
 
 
Conclusion 
 
 Stem cell therapies continue to 
revolutionize many fields of medicine. To 
build that momentum, research must 
continue to be done into this promising field. 
Central to any biomedical research is the use 
of models to simulate how a particular 
therapy of interest behaves in vivo. A model 
should be relatively simple and well-
characterized. By having well-defined 
models, one is able to answer important 
questions without risking resources or lives 
in later trials.  
 
The research into many details 
concerning MC 3T3-E1 cells has given that 
crucial definition to the Dhar lab. We have 
shown the characteristics and ideal 
conditions of these cells; we have shown 
inductive factors and timelines for their 
differentiation into bone tissues; we have 
shown how they respond to drugs that will be 
used in subsequent in vivo trials; and we are 
using these findings to discover new ways of 
visualizing them and of using them in 
regenerative medicine. The use of the MC 
3T3-E1 cell line will serve as a crucial tool to 
explore many new therapies in the Dhar lab
Figure 5.  Preliminary experiments show 
successful transfection of the positive control 
plasmid with only m-cherry using PEI 
Figure 6.  Cytoplasmic staining of MC 3T3-E1 
cells grown on the polymer-hydroxyapatite 
biomaterial. 
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